Rose Hip and osteoarthritis
What 4 graded rows on rose hip agree on for osteoarthritis, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Rose Hip page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Rose Hip page, with its PubMed record.
Your question
Rose Hip and osteoarthritis
4 rows · 613 peopleMostly an improvement: 3 of 4 rows, and most of the people. 1 found no difference.
- CGrade C× 2
- DGrade D× 2
- Rows
- 4
- Trials
- 6
- People
- 613
- Pooled reviews may count some twice
Where they differ
From the rowsThe best-graded row, grade C, is a meta-analysis of 287 people (2008) and found an improvement.
Only the 3 rows that found an improvement include pooled reviews of several trials (1 of 3); the row that found no difference is a single study.
The row that found no difference is newer (2026) than the 3 rows that found an improvement (2004 to 2008).
The rows
3 improved · 1 no difference- CGrade COsteoarthritis pain · Improved
Meta-analysis, 3 studies · n 287 · 2008 · Adults with osteoarthritis in 3 RCTs
Varied (5 g/day in the two crossover trials cited here) · Median 3 months
Pain fell more than with placebo (effect size 0.37), and patients were about twice as likely to respond (OR 2.19), a number needed to treat of 6.
- DGrade DOsteoarthritis joint pain and stiffness · Improved
Crossover RCT · n 112 · 2004 · Adults with osteoarthritis
5 g/day · 3 months per period
In the group given placebo first, pain and stiffness improved more on rose hip; in the group given rose hip first, placebo appeared to work as well, which the authors attribute to carryover. In the first 3 months, 66% responded on rose hip versus 36% on placebo; no major side effects.
- DGrade DHip and knee osteoarthritis pain, stiffness and rescue-medication use · Improved
Crossover RCT · n 94 · 2005 · Adults with hip or knee osteoarthritis
5 g/day · 3 months per period
WOMAC pain fell versus placebo by 3 weeks and rescue-medication use declined; disability, stiffness and global severity improved by 3 months.
- CGrade CHip and knee osteoarthritis pain and function · No difference
RCT · n 120 · 2026 · Adults with mild to moderate hip or knee osteoarthritis (multicentre trial NCT01459939), 60 per group
5 g/day for 3 weeks, then 2.5 g/day · 12 weeks
WOMAC pain and function improved by more than 50% in both groups, with no significant difference between rose hip and placebo. A secondary analysis found larger improvement with a higher dose per kg of body weight in the rose hip group only.